Ending the evidence gap for pregnancy, HIV and co-infections: ethics guidance from the PHASES project.
HIV
co-infections
ethics
pregnancy
prevention
research
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
15
06
2021
accepted:
21
10
2021
entrez:
15
12
2021
pubmed:
16
12
2021
medline:
28
12
2021
Statut:
ppublish
Résumé
While pregnant people have been an important focus for HIV research, critical evidence gaps remain regarding prevention, co-infection, and safety and efficacy of new antiretroviral therapies in pregnancy. Such gaps can result in harm: without safety data, drugs used may carry unacceptable risks to the foetus or pregnant person; without pregnancy-specific dosing data, pregnant people face risks of both toxicity and undertreatment; and delays in gathering evidence can limit access to beneficial next-generation drugs. Despite recognition of the need, numerous barriers and ethical complexities have limited progress. We describe the process, ethical foundations, recommendations and applications of guidance for advancing responsible inclusion of pregnant people in HIV/co-infections research. The 26-member international and interdisciplinary Pregnancy and HIV/AIDS: Seeking Equitable Study (PHASES) Working Group was convened to develop ethics-centred guidance for advancing timely, responsible HIV/co-infections research with pregnant people. Deliberations over 3 years drew on extensive qualitative research, stakeholder engagement, expert consultation and a series of workshops. The guidance, initially issued in July 2020, highlights conceptual shifts needed in framing research with pregnant people, and articulates three ethical foundations to ground recommendations: equitable protection from drug-related risks, timely access to biomedical advances and equitable respect for pregnant people's health interests. The guidance advances 12 specific recommendations, actionable within the current regulatory environment, addressing multiple stakeholders across drug development and post-approval research, and organized around four themes: building capacity, supporting inclusion, achieving priority research and ensuring respect. The recommendations describe strategies towards ethically redressing the evidence gap for pregnant people around HIV and co-infections. The guidance has informed key efforts of leading organizations working to advance needed research, and identifies further opportunities for impact by a range of stakeholder groups. There are clear pathways towards ethical inclusion of pregnant people in the biomedical research agenda, and strong agreement across the HIV research community about the need for - and the promise of - advancing them. Those who fund, conduct, oversee and advocate for research can use the PHASES guidance to facilitate more, better and earlier evidence to optimize the health and wellbeing of pregnant people and their children.
Identifiants
pubmed: 34910846
doi: 10.1002/jia2.25846
pmc: PMC8673925
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25846Subventions
Organisme : NIAID NIH HHS
ID : R01 AI127024
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI108368
Pays : United States
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Informations de copyright
© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Expert Opin Pharmacother. 2018 Nov;19(16):1779-1796
pubmed: 30289730
N Engl J Med. 2019 Aug 29;381(9):827-840
pubmed: 31329379
J Acquir Immune Defic Syndr. 2021 Apr 15;86(5):607-615
pubmed: 33298793
Lancet. 2019 Nov 30;394(10213):1972-1974
pubmed: 31789207
Clin Pharmacol Ther. 2021 Jul;110(1):36-48
pubmed: 32930408
J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):181-8
pubmed: 26361171
Clin Infect Dis. 2019 Sep 13;69(7):1254-1258
pubmed: 30783649
Lancet Glob Health. 2021 Mar;9(3):e366-e371
pubmed: 33340453
J Med Ethics. 2017 Oct;43(10):664-665
pubmed: 28716976
J Womens Health (Larchmt). 2019 Jan;28(1):93-99
pubmed: 30124366
N Engl J Med. 2019 Oct 3;381(14):1333-1346
pubmed: 31577875
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
J Thorac Dis. 2018 May;10(5):3102-3118
pubmed: 29997980
Vaccine. 2021 Feb 5;39(6):868-870
pubmed: 33446385
Clin Infect Dis. 2017 Oct 15;65(8):1383-1387
pubmed: 29017245
Reprod Health. 2017 Dec 14;14(Suppl 3):156
pubmed: 29297373
Br J Clin Pharmacol. 2021 May 14;:
pubmed: 33990968
AIDS Res Ther. 2020 May 27;17(1):27
pubmed: 32460804
Obstet Gynecol. 2015 Nov;126(5):e100-7
pubmed: 26488521
Clin Infect Dis. 2016 Mar 15;62(6):761-769
pubmed: 26658057
J Infect Dis. 2018 Jun 5;218(1):16-25
pubmed: 29514254
Am J Bioeth. 2020 Feb;20(2):5-19
pubmed: 31990253
J Int AIDS Soc. 2021 Mar;24(3):e25680
pubmed: 33665978
Sex Transm Infect. 2014 Aug;90(5):363-9
pubmed: 24898857
Reprod Health. 2017 Dec 14;14(Suppl 3):172
pubmed: 29297366
PLoS Med. 2019 Sep 20;16(9):e1002895
pubmed: 31539371
Clin Infect Dis. 2014 Dec 15;59 Suppl 7:S437-44
pubmed: 25425722
Int J Fem Approaches Bioeth. 2008 Fall;1(2):5-22
pubmed: 19774226
Clin Pharmacol Ther. 2021 Oct;110(4):941-945
pubmed: 33615448
AIDS. 2016 Sep 24;30(15):2261-5
pubmed: 27490637
J Empir Res Hum Res Ethics. 2018 Oct;13(4):349-362
pubmed: 29998787
PLoS Med. 2019 Aug 15;16(8):e1002882
pubmed: 31415563
Int J Gynaecol Obstet. 2014 Nov;127(2):213-5
pubmed: 25097142
Lancet. 2021 Apr 3;397(10281):1276-1292
pubmed: 33812487
Lancet HIV. 2020 May;7(5):e332-e339
pubmed: 32386721
Science. 2010 Sep 3;329(5996):1168-74
pubmed: 20643915
PLoS One. 2019 May 8;14(5):e0216332
pubmed: 31067273